Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women ≥18 years of age.
Histologically confirmed diagnosis of a solid tumor malignancy documented by cytology or biopsy.
Presence of metastatic disease.
Hemoglobin value between ≥8.0 to \<11.0 g/dL (≥80 to \<110 g/L).
≥28 days must have elapsed (prior to pre-dose red blood cell mass / plasma volume test) since previous treatment with erythropoiesis-stimulating agent (including concurrent treatment with intravenous \[IV\] iron).
≥28 days must have elapsed (prior to Day 1) since the last red blood cell transfusion and receipt of ≤2 units of blood in the past 56 days (prior to Day 1).
Eastern Cooperative Oncology Group (ECOG) Performance status of 0 - 1.
You may not be if
At the time of screening, participants who have any grade ≥3 toxicity (according to the currently active minor version of NCI CTCAE v4.0) except for the following disease-related toxicities:
Non-hematological events - nausea, vomiting, fatigue, muscle or bone/joint pain
Clareo Health | Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors
